NOVEL OPPORTUNITIES TO REACH THE TARGET LEVELS OF LOW DENSITY CHOLESTEROL
https://doi.org/10.15829/1728-8800-2014-4-60-63
Abstract
The article concerns prevalence and efficacy of primary and secondary preventive strategies for hyperlipidemia in Russian Federation. According to the European Guidelines 2013 for Treatment of Stable Ischemic Heart Disease and the American Guidelines for Hypercholestrolemia, the article emphasizes that the main drug class that is effective in prognosis improvement, are statins, without mentioning any specific name. Among the higher cardiovascular risk categories it is possible to use high doses or intensive regimen of the two most common statins: atorvastatin and rozuvastatin. The results of the largest meta-analysis VOYAGER with 32 thousands patients, are provided, showing more success against other statins to reach target low density cholesterol levels.
About the Author
M. V. Ezhov
The Institute for Clinical Cardiology n.a. Myasnikov A.L. FSBI "RCSPC" of the Ministry of Health, Moscow
Russian Federation
tel./fax: 8 (495) 414–60–67
Russian Federation
tel./fax: 8 (495) 414–60–67
References
1. Russian Statistical Yearbook 2013. www.gks.ru. Russian (Российский статистиче- ский ежегодник 2013).
2. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949–3003.
3. Reiner Ž, De Bacquer D, Kotseva K, et al.; EUROASPIRE III Study Group. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis 2013; 231: 300–7.
4. Boytsov SA, on behalf of the Russian Federation Working Group. Prevalence of cardiovascular risk factors and cardiovascular prevention quality in primary healthcare in Russia and European countries: EURIKA Study results. Cardiovascular Therapy and Prevention 2012; 11 (1): 11–6. Russian (Бойцов С.А. от коллектива исследователей в Российской Федерации. Структура факторов сердечно- сосудистого риска и качество мер их профилактики в первичном звене здра- воохранения в России и в Европейских странах (по результатам исследования EURIKA). Кардиоваскулярная терапия и профилактика 2012; 11 (1): 11–6).
5. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
6. Oganov RG, Kukharchuk VV, Arutyunov GP, et al. on behalf of the researchers DYSIS. Continuing violations of lipid profile in patients with dyslipidemia receiving statins in clinical practice in the Russian Federation (Russian part of the study DYSIS). Cardiovascular Therapy and Prevention 2012; 11 (4): 70–8. Russian (Оганов Р. Г., Кухарчук В.В., Арутюнов Г. П. и др. от имени исследователей DYSIS. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика 2012; 11 (4): 70–8.
7. Catapano AL, Reiner Z, De Backer G, et al; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3–46.
8. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation 2014; 129: S1–45.
9. Morris PB, Ballantyne CM, Birtcher KK, et al. Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. JACC 2014; 64: 196–206.
10. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010; 105: 69–76.
11. Karlson BW, Nicholls SJ, Lundman P, et al. Achievement of 2011 European lowdensity lipoprotein cholesterol (LDL–C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER. Atherosclerosis 2013; 228: 265–9.
12. Karlson BW, Barter PJ, Palmer MK, et al. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis 2012; 22: 697–703.
Review
For citations:
Ezhov M.V. NOVEL OPPORTUNITIES TO REACH THE TARGET LEVELS OF LOW DENSITY CHOLESTEROL. Cardiovascular Therapy and Prevention. 2014;13(4):60-63. (In Russ.) https://doi.org/10.15829/1728-8800-2014-4-60-63
Views:
666
Email this article 
